This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kievit, E. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Kievit, E. Articles by Lawrence, T. S.

Yeast Cytosine Deaminase Improves Radiosensitization and Bystander Effect by 5-Fluorocytosine of Human Colorectal Cancer Xenografts¹

Departments of Radiation Oncology [E. K., M. K. N., E. N., A. R., T. S. L.], Radiology and Biological Chemistry [L. D. S., B. D. R.], and Pharmacology [J. P.], University of Michigan, Ann Arbor, Michigan 48109-0010

The efficacy of cancer gene therapy using bacterial cytosine deaminase (bCD)/5-fluorocytosine (5-FC) enzyme/prodrug strategy is limited by the inefficiency of cytosine deaminase (CD)-catalyzed conversion of 5-FC into 5-fluorouracil (5-FU). We have shown previously that yeast CD (yCD) is more efficient at the conversion of 5-FC than bCD. In the current study, we hypothesized that the increased production of 5-FU by yCD would enhance the efficacy of the CD/5-FC treatment strategy by increasing the bystander effect as well as the efficacy of radiotherapy because of the radiosensitizing capacity of 5-FU. To test this hypothesis, we generated stable HT29 human colon cancer cell lines expressing either bCD (HT29/bCD) or yCD (HT29/yCD). The amount of 5-FU produced in HT29/yCD tumors after a single injection of 5-FC (1000 mg/kg, i.p.) was 15-fold higher than that produced in HT29/bCD tumors. In tumor-bearing nude mice, the average minimum relative tumor size (compared with pretreatment values) of HT29/bCD tumors treated with 5-FC and radiation (500 mg/kg i.p. and 3 Gy, 5 days a week for 2 weeks) was 0.55 ± 0.1, compared with 0.01 ± 0.01 in HT29/yCD tumors (P = 0.002). Moreover, an increased cytotoxic and radiosensitizing effect of 5-FC on bystander cells was observed in vitro and in vivo when yCD was expressed in HT29 cells instead of bCD. In mice bearing HT29 tumors containing 10% HT29/yCD cells, the combined treatment resulted in a minimum tumor size of 0.20 ± 0.07 compared with 0.60 ± 0.1 in 10% HT29/bCD cells (P < 0.001). These results demonstrate that the use of yCD in the CD/5-FC strategy has a high potential to improve the therapeutic outcome of combined gene therapy and radiotherapy in cancer patients.

This article has been cited by other articles:

				L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy Cancer Res., July 1, 2007; 67(13): 6304 - 6313. [Abstract] [Full Text] [PDF]

				H. Akbulut, Y. Tang, K. G. Akbulut, J. Maynard, L. Zhang, and A. Deisseroth Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 1975 - 1985. [Abstract] [Full Text] [PDF]

				M. Porosnicu, A. Mian, and G. N. Barber The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus Is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene Cancer Res., December 1, 2003; 63(23): 8366 - 8376. [Abstract] [Full Text] [PDF]

				S. O. Freytag, H. Stricker, J. Pegg, D. Paielli, D. G. Pradhan, J. Peabody, M. DePeralta-Venturina, X. Xia, S. Brown, M. Lu, et al. Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7497 - 7506. [Abstract] [Full Text] [PDF]

				M. Ramnaraine, W. Pan, M. Goblirsch, C. Lynch, V. Lewis, P. Orchard, P. Mantyh, and D. R. Clohisy Direct and Bystander Killing of Sarcomas by Novel Cytosine Deaminase Fusion Gene Cancer Res., October 15, 2003; 63(20): 6847 - 6854. [Abstract] [Full Text] [PDF]

				T.-P. Ko, J.-J. Lin, C.-Y. Hu, Y.-H. Hsu, A. H.-J. Wang, and S.-H. Liaw Crystal Structure of Yeast Cytosine Deaminase: INSIGHTS INTO ENZYME MECHANISM AND EVOLUTION J. Biol. Chem., May 23, 2003; 278(21): 19111 - 19117. [Abstract] [Full Text] [PDF]

				M. Zhang, S. Li, M. K. Nyati, S. DeRemer, J. Parsels, A. Rehemtulla, W. D. Ensminger, and T. S. Lawrence Regional Delivery and Selective Expression of a High-Activity Yeast Cytosine Deaminase in an Intrahepatic Colon Cancer Model Cancer Res., February 1, 2003; 63(3): 658 - 663. [Abstract] [Full Text] [PDF]

				M. K. Nyati, A. Sreekumar, S. Li, M. Zhang, S. D. Rynkiewicz, A. M. Chinnaiyan, A. Rehemtulla, and T. S. Lawrence High and Selective Expression of Yeast Cytosine Deaminase under a Carcinoembryonic Antigen Promoter-Enhancer Cancer Res., April 1, 2002; 62(8): 2337 - 2342. [Abstract] [Full Text] [PDF]